Evolocumab
Brand name: Repatha Sureclick
Rank #40 of 500 drugs by total cost
$460.5M
Total Cost
528,560
Total Claims
$460.5M
Total Cost
14,741
Prescribers
$871
Cost per Claim
54,056
Beneficiaries
779,525
30-Day Fills
$31K
Avg Cost/Provider
36
Avg Claims/Provider
About Evolocumab
Evolocumab (sold as Repatha Sureclick) was prescribed 528,560 times by 14,741 Medicare Part D providers in 2023, costing the program $460.5M. At $871 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 37 | Tafamidis (Vyndamax) | $511.1M | 20,589 |
| 38 | Fluticasone/Vilanterol (Breo Ellipta) | $493.0M | 909,837 |
| 39 | Tiotropium Bromide (Spiriva Handihaler) | $478.1M | 673,800 |
| 40 | Evolocumab (Repatha Sureclick) | $460.5M | 528,560 |
| 41 | Acalabrutinib Maleate (Calquence) | $457.0M | 31,890 |
| 42 | Atorvastatin Calcium (Atorvastatin Calcium) | $444.6M | 30,263,929 |
| 43 | Osimertinib Mesylate (Tagrisso) | $436.5M | 25,273 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology